US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.62 -0.61 (-3.17%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
News headline image
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗
Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes. 
Via Stocktwits
Topics Intellectual Property
News headline image
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment. 
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
From Sarepta Therapeutics, Inc.
Via Business Wire
Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗
Via Stocktwits
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗
Via Stocktwits
News headline image
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
From Sarepta Therapeutics, Inc.
Via Business Wire
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Beaten-Down Stocks That Could Sink Even More in 2026 ↗
Don't catch a falling knife. 
Via The Motley Fool
Topics Death
News headline image
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Why Is SRPT Stock Falling Today? ↗
Sarepta Therapeutics announced a debt refinancing plan totaling about $291 million. 
Via Stocktwits
News headline image
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
New York, NY – December 9, 2025 – Dyne Therapeutics (NASDAQ: DYN) found itself in an unusual spotlight today, emerging as a significant market mover, albeit in a direction that belied ostensibly... 
Via MarketMinute
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam. 
Via Investor's Business Daily
News headline image
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗
The data from the study cohort will be used to determine whether administering sirolimus before and after the ELEVIDYS infusion can help reduce acute liver injury, the company said. 
Via Stocktwits
News headline image
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Tech Edges Up Ahead Of Nvidia's Earnings, Bitcoin Sinks Below $90,000: What's Moving Markets Wednesday? ↗
All eyes are on Nvidia Corp. (NASDAQ:NVDA) as the world's most valuable company prepares to report third-quarter earnings after the close, a pivotal moment that could steer 
Via Benzinga
News headline image
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy ↗
FDA added a boxed warning to Elevidys after two pediatric deaths and imposed stricter monitoring rules. 
Via Stocktwits
Topics Death
News headline image
2 Beaten-Down Stocks to Avoid Right Now ↗
There might be plenty more downside for these biotechs. 
Via The Motley Fool
Topics Death
News headline image
Sarepta Shares Jump After FDA Approves Updated Elevidys Label ↗
Sarepta Therapeutics shares jumped after the FDA issued a new boxed warning for Elevidys. 
Via Benzinga
News headline image
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge
The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >